Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.

Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.This stu...

Full description

Bibliographic Details
Main Authors:	Åsa Alsiö, Karolina Rembeck, Galia Askarieh, Peer Brehm Christensen, Martti Färkkilä, Nina Langeland, Mads Rauning Buhl, Court Pedersen, Kristine Mørch, Bart L Haagmans, Salmir Nasic, Johan Westin, Kristoffer Hellstrand, Gunnar Norkrans, Martin Lagging
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3360051?pdf=render

Similar Items

Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3.
by: Karolina Rembeck, et al.
Published: (2012-01-01)

A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis.
by: Magdalena Ydreborg, et al.
Published: (2014-01-01)

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection.
by: Jesper Waldenström, et al.
Published: (2016-01-01)

<it>PNPLA 3</it> I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
by: Rembeck Karolina, et al.
Published: (2012-09-01)

Core mutations, <it>IL28B </it>polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
by: Wahlberg Thomas, et al.
Published: (2011-05-01)

Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done?
by: Donald M. Jensen
Published: (2009-01-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
by: Calza Leonardo, et al.
Published: (2010-05-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Impact of obesity on outcome of severe bacterial infections.
by: Åsa Alsiö, et al.
Published: (2021-01-01)

Psychosis during peginterferon-alpha2a and ribavirin therapy: case report
by: Lucas C. Quarantini, et al.

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012-06-01)

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection
by: Maribel Rodriguez-Torres, et al.
Published: (2016-11-01)

The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in HCV-Infected Patients
by: Javad Moayedi, et al.
Published: (2020-08-01)

Outcomes of Peginterferon Alpha-2a and Ribavirin Hepatitis C therapy in Aboriginal Canadians
by: Curtis L Cooper, et al.
Published: (2008-01-01)

Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin
by: Delić Dragan, et al.
Published: (2005-01-01)

Efficacy and safety of peginterferon combined with ribavirin in treating older patients with chronic hepatitis C
by: Chung-Feng Huang, et al.
Published: (2009)

The oxidative and antioxidative status in chronic hepatitis C patients treated with peginterferon and ribavirin therapy
by: Ｙi-hui Chen, et al.
Published: (2008)

Outcome, Cost and Quality of life for chronic hepatitis C patients treated by peginterferon and ribavirin
by: Ming-Kun Ku, et al.
Published: (2010)

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
by: Alejandro Soza, M.D., et al.
Published: (2015-01-01)

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
by: Ming-Yen Hsieh, et al.
Published: (2012-02-01)

Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
by: Ming-Lung Yu, et al.
Published: (2012-01-01)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
by: Ide K, et al.
Published: (2016-03-01)

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C
by: Mohammed Eslam, et al.
Published: (2011-04-01)

The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
by: Jesper Waldenström, et al.
Published: (2020-01-01)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
by: Robert Flisiak, et al.
Published: (2016-01-01)

Superiority of peginterferon α-2a and ribavirin combination over peginterferon α-2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infection
by: Saeed M.G Al-Ghamdi, et al.
Published: (2017-01-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
by: Marcelo Cunio Machado Fonseca, et al.

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
by: Seok Hoo Jeong, et al.
Published: (2012-12-01)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
by: Zehui Yan, et al.
Published: (2012-01-01)

Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon 𝜶-2a and Ribavirin
by: M. Kondo, et al.
Published: (2011-01-01)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
by: Ming-Te Kuo, et al.
Published: (2014-01-01)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
by: Wei-Hsin Ko, et al.
Published: (2006)

Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection
by: Ching-Chung Lin, et al.
Published: (2014-07-01)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
by: Zongguo Yang, et al.
Published: (2013-01-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.
Published: (2012-09-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
by: Osamu Yokosuka, et al.
Published: (2012-08-01)